National Academy of Sciences Mini-Symposium Part 2
to
NIH videocast
Join us for "part 2" of our annual National Academy of Sciences Mini-Symposium! On November 13, we will hear inspirational, 30-minute lectures from two of our distinguished principal investigators — Drs. Sandra Wolin and Steven Rosenberg — elected to the NAS in 2024. Part one, took place on Sept. 24.
Dr. Wolin's laboratory studies how noncoding RNAs function, how cells recognize and degrade defective RNAs, and how failure to degrade these RNAs affects cell function and contributes to human disease. Most cellular RNA does not encode proteins, and truncated, misfolded and aberrant RNAs can accumulate due to mutations, transcriptional errors, and processing mistakes. Some forms of environmental stress, such as exposure to oxidants and ultraviolet light, result in RNA damage, yet little is known of how damaged RNAs are recognized and handled.
Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He has also pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. His recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas, and lymphomas.
This page was last updated on Tuesday, November 5, 2024